drugset / Trial / NCT05025605
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
Timeline
- Start
- 2021-08-27
- Primary completion
- 2027-07-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexmedetomidine | Other / unclassified | 60 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 80 ug | Other |
| Subject | Dexmedetomidine | Other / unclassified | 120 ug | Other |